M. Purtscher

Learn More
In view of the high antigenic variability of human immunodeficiency virus type 1 (HIV-1), a vaccine against AIDS must induce an immune response to epitopes as invariable as possible among the various virus strains and clones. Previously the highly conserved six amino acid sequence Glu-Leu-Asp-Lys-Trp-Ala (ELDKWA) from gp41, defining the epitope of the human(More)
Although typical primary isolates of human immunodeficiency virus type 1 (HIV-1) are relatively neutralization resistant, three human monoclonal antibodies and a small number of HIV-1(+) human sera that neutralize the majority of isolates have been described. The monoclonal antibodies (2G12, 2F5, and b12) represent specificities that a putative vaccine(More)
We have developed a μ-fluidic biochip capable of monitoring in real-time cellular phenotype dynamics by non-invasively assessing cell viability and reproduction over long periods of time. The μ-fluidic biochip contains integrated organic photodiodes that continuously perform light scattering measurements of adherent cell populations. In the(More)
  • 1